Jubilant Pharmova Ltd.

•

jubilantpharmova.comBSE: 530019NSE: JUBLPHARMA

Market Cap₹ 16,328 Cr.

Current Price

High / Low₹ 1,185 / 786

Stock P/E46.4

Book Value₹ 448

Price to Book1.82

Dividend Yield0.49 %

ROCE8.7 %

ROE6.0 %

Face Value₹ 1

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2026 • Radiopharma: 44.3% • Contract Development & Manufacturing Organisation Sterile Injectables: 21.7% • Contract Research & Development Services: 15.2%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Strong cash generation - operating cash flow backs reported profits (CFO/PAT 2.50x)
Company has a consistent dividend-paying track record
Company generates healthy free cash flow
Company maintains a comfortable, low leverage position

CONS

Recent results are weak - TTM profit is down 30.8% versus prior year
Company has a low return on capital employed of 9.2%
Company has a low return on equity of 7.2% over last 3 years
Promoter holding has decreased over last 2 years: -3.0pp
Company has delivered a poor profit growth of -7.1% over past five years
Recurring exceptional / one-off items are inflating headline profit

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY TOTAL MKT NIFTY 500 NIFTY SMLCAP 250

S.No.	Name
1.	SUNPHARMA	1842.00	36.54	441957.50	0.87	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9326.00	84.64	247576.00	0.32	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4975.00	86.76	189233.01	0.76	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1119.50	24.74	111670.55	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1365.00	32.72	110272.68	0.95	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1970.35	97.37	106460.42	0.10	362.07	123.94	2026.31	29.10	18.20	31.50
7.	DRREDDY	1161.00	30.07	96906.38	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
8.	AUROPHARMA	1675.45	25.97	96401.69	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
9.	LUPIN	2096.00	17.34	95842.92	0.86	1416.98	16.01	8276.89	34.28	28.86	29.59
10.	MANKIND	2277.00	46.04	94050.37	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
11.	GLENMARK	2416.90	37.94	68210.88	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	JUBLPHARMA	1025.10	46.37	16327.91	0.49	56.40	-44.98	2229.40	18.65	8.69	11.12

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	1,566	1,667	1,665	1,746	1,720	1,742	1,814	1,916	1,879	1,958	2,116	2,272	2,229
	1,417	1,438	1,459	1,487	1,480	1,463	1,534	1,583	1,611	1,625	1,833	1,951	2,163
Operating Profit	149	228	206	259	240	279	279	332	268	333	283	321	66
OPM %	9.52%	13.69%	12.38%	14.84%	13.96%	16.03%	15.40%	17.35%	14.25%	17.00%	13.38%	14.15%	2.98%
	9	10	36	-154	410	8	-10	9	12	4	-19	10	20
Interest	62	66	71	73	71	61	56	53	49	50	56	56	54
Depreciation	90	97	95	101	91	91	91	95	98	105	121	117	127
Profit before Tax	27	89	88	-57	500	144	131	206	154	190	94	176	86
Tax %	72.18%	40.34%	39.36%	-14.19%	3.58%	29.00%	22.78%	26.54%	33.59%	36.97%	40.21%	32.22%	34.72%
Net Profit	0	0	0	0	482	102	101	151	102	120	56	119	56
	0.40	3.94	4.22	-3.69	30.44	6.47	6.37	9.71	6.49	7.59	3.52	7.55	3.57

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	5,861	7,518	9,111	5,976	6,099	6,130	6,282	6,703	7,234	8,280	8,576
	4,516	5,999	7,372	4,428	4,702	4,974	5,506	5,802	6,061	7,020	7,572
Operating Profit	1,345	1,518	1,739	1,548	1,396	1,156	776	901	1,174	1,260	1,004
OPM %	22.95%	20.20%	19.09%	25.90%	22.90%	18.86%	12.36%	13.44%	16.22%	15.22%	11.71%
	25	40	-244	4	-4	11	-18	-100	416	7	15
Interest	341	284	220	200	184	145	188	272	240	212	217
Depreciation	291	415	371	340	349	382	554	382	369	440	470
Profit before Tax	738	859	904	1,013	871	630	28	170	981	614	546
Tax %	22.10%	26.15%	36.16%	33.08%	34.12%	34.49%	333.45%	57.36%	14.72%	35.27%	35.64%
Net Profit	575	634	577	678	574	413	-65	73	836	398	352
EPS	36.91	41.25	36.86	56.39	52.48	26.00	-3.83	4.88	53.13	25.22	—
Dividend Payout %	8.12%	7.27%	12.48%	8.87%	9.52%	19.23%	-130.33%	102.47%	9.41%	19.82%	—

COMPOUNDED SALES GROWTH

10 Years:: 4%
5 Years:: 6%
3 Years:: 10%

COMPOUNDED PROFIT GROWTH

10 Years:: 0%
5 Years:: -14%
3 Years:: —

STOCK PRICE CAGR

10 Years:: 7%
5 Years:: 10%
3 Years:: 33%
1 Year:: -9%

RETURN ON EQUITY

10 Years:: 10%
5 Years:: 6%
3 Years:: 7%
Last Year:: 6%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	16	16	16	16	16	16	16	16	16	16
Minority Interest	-47	-52	0	0	0	-2	-8	-13	-16	3
	3,420	4,071	4,793	5,588	4,725	5,299	5,377	5,404	6,224	7,058
	4,241	3,729	4,851	4,773	2,806	3,148	3,852	4,124	4,281	5,640
Trade Payables	749	1,136	1,020	1,090	520	568	821	856	1,005	1,234
	520	557	639	843	696	802	870	929	990	1,315
Total Liabilities	8,899	9,457	11,319	12,310	8,763	9,830	10,929	11,316	12,499	15,266
	5,107	5,401	5,648	6,340	4,609	4,871	5,183	5,091	5,176	6,966
Capital Work in Progress	211	300	492	264	278	292	773	1,252	2,715	2,962
	103	124	115	69	241	239	256	42	44	61
	1,220	1,391	1,417	1,845	1,129	1,255	1,380	1,290	1,129	1,232
	0	0	0	0	0	0	0	916	892	1,070
Cash & Bank	460	249	1,370	1,400	671	984	1,014	957	1,089	1,268
	1,799	1,993	2,276	2,392	1,835	2,189	2,321	1,768	1,456	1,708
Total Assets	8,899	9,457	11,319	12,310	8,763	9,830	10,929	11,316	12,499	15,266

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,412	1,561	1,465	1,792	2,178	1,032	865	971	1,072	1,227
Cash from Investing	-450	-618	-1,012	-327	-739	-380	-544	-608	488	-1,260
Cash from Financing	-686	-901	657	-1,050	-1,709	-33	-157	-432	-1,453	95
	132	-216	767	166	-664	425	-40	-69	107	62

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026

Shareholding Pattern

Numbers in percentages

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	50.68	50.68	50.68	50.68	47.68	47.68	47.68	47.68	47.68
	19.50	17.94	16.96	17.23	17.40	16.56	15.96	15.90	15.87
	4.06	5.66	6.98	7.04	9.52	10.53	11.23	11.63	12.40
Government	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	25.77	25.73	25.39	25.06	25.40	25.24	25.14	24.80	24.05

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-11

General Updates

2026-09-11 - Jubilant Pharmova Limited has informed the Exchange about General Updates

2026-09-01

General Updates

2026-09-01 - Jubilant Pharmova Limited has informed the Exchange about General Updates - Receipt of Show Cause Notice by Jubilant Pharmova Limited - GST

2026-08-29

Copy of Newspaper Publication

2026-08-29 - Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication - Re-lodgement and KYC Updation

2026-08-28

General Updates

2026-08-28 - Jubilant Pharmova Limited has informed the Exchange about General Updates

2026-08-26

Shareholders meeting

2026-08-26 - Jubilant Pharmova Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 26, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.

2026-08-23

General Updates

2026-08-23 - Jubilant Pharmova Limited has informed the Exchange about General Updates-USFDA Approval for Line 3, Contract manufacturing facility, Spokane, U.S.A

2026-08-17

Shareholders meeting

2026-08-17 - Jubilant Pharmova Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.

2026-08-11

Copy of Newspaper Publication

2026-08-11 - Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-10

Press Release

2026-08-10 - Jubilant Pharmova Limited has informed the Exchange regarding a press release dated August 10, 2026, titled "The Company has informed the Exchange regarding press release dated August 10, 2026".

News

Recent coverage and analyst commentary for JUBLPHARMA

Loading news…

🤖

AI Stock Analyst

Jubilant Pharmova Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account